AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28177714 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein intake (HiPROT) at 1.45 g protein/(kg body mass·day) plus 0.72 g branched-chain amino acids per day during BR
Number of subjects: 16
Study 28177714 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group receiving 1 g/(kg body mass·day) dietary protein
Number of subjects: 16
Study 25587171 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractive Auditory Stimuli (DAS)
Number of subjects: 16
Study 25587171 — intervention group
Group type: COMPARATOR
Intervention: Control (no DAS)
Number of subjects: 16
Study 23263742 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate solution (PRO) - 20 g before, 10 g during, 20 g post-exercise
Number of subjects: 10
Study 23263742 — intervention group
Group type: COMPARATOR
Intervention: Non-calorie taste matched placebo (PLA)
Number of subjects: 10
Study 21511816 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 2102
Study 21511816 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 2102
Study 19082328 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative physiotherapy (G1)
Number of subjects: 135
Study 19082328 — intervention group
Group type: COMPARATOR
Intervention: Postoperative physiotherapy only (G2)
Number of subjects: 135
Study 16877725 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) 600 units/kg to 900 units/kg, administered intravenously once-weekly for 16 weeks
Number of subjects: 222
Study 16877725 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered once-weekly for 16 weeks
Number of subjects: 222
Study 12969089 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg o.d., amoxicillin 1 g b.d., rabeprazole 20 mg b.d. for 10 days (LAR)
Number of subjects: 280
Study 12969089 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg o.d., tinidazole 500 mg b.d., rabeprazole 20 mg b.d. for 10 days (LTR)
Number of subjects: 280
Study 12969089 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 500 mg q.d.s., metronidazole 500 mg t.d.s., bismuth salt 120 mg q.d.s., rabeprazole 20 mg b.d. for 7 days (7TMBR)
Number of subjects: 280
Study 12969089 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 500 mg q.d.s., metronidazole 500 mg t.d.s., bismuth salt 120 mg q.d.s., rabeprazole 20 mg b.d. for 14 days (14TMBR)
Number of subjects: 280
Study 10883418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 24
Study 10883418 — intervention group
Group type: COMPARATOR
Intervention: Fasting treatment
Number of subjects: 24
Study 9013268 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) patients
Number of subjects: 77
Study 9013268 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (controls)
Number of subjects: 77
Study 9013268 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable angina and acute coronary syndromes (ACS) patients
Number of subjects: 77
Study 1530028 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day 0 (group II)
Number of subjects: 25
Study 1530028 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +12 (group V)
Number of subjects: 25
Study 1530028 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +4 (group IV)
Number of subjects: 25
Study 1530028 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +4 (group IV) and +8 (group III)
Number of subjects: 25
Study 1530028 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group I)
Number of subjects: 25
Study 1530028 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +8 (group III)
Number of subjects: 25
Study 6362819 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and Adriamycin (doxorubicin) added to an alkylating agent‐prednisone combination
Number of subjects: 256
Study 6362819 — intervention group
Group type: COMPARATOR
Intervention: Two alternating drug combinations
Number of subjects: 256
Study 6362819 — intervention group
Group type: COMPARATOR
Intervention: Levamisole during remission maintenance
Number of subjects: 256
Study 31181357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 300,000 IU vitamin D before surgery
Number of subjects: 60
Study 31181357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 60
Study 30829271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound-guided excision
Number of subjects: 60
Study 30829271 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation-guided excision
Number of subjects: 60
Study 26395774 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted weight loss maintenance intervention (individual face-to-face consultation, mobile internet platform for self-monitoring diet, activity, and weight, automated feedback via mobile phone)
Number of subjects: 288
Study 26395774 — intervention group
Group type: COMPARATOR
Intervention: Quarterly newsletters and wirelessly connected scales (control group)
Number of subjects: 288
Study 23020955 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 49
Study 23020955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 49
Study 23020955 — intervention group
Group type: COMPARATOR
Intervention: Control (Tab. Glucose)
Number of subjects: 49
Study 22180399 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate chemotherapy
Number of subjects: 1442
Study 22180399 — intervention group
Group type: COMPARATOR
Intervention: Delayed chemotherapy
Number of subjects: 1442
Study 19548490 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex Master
Number of subjects: 70
Study 19548490 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Taper
Number of subjects: 70
Study 19548490 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 70
Study 17530982 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (cycling for 20 minutes each day, 3 times per week, for 6 weeks at 70% of VO2max)
Number of subjects: 21
Study 15155323 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (placebo capsule preoperatively and IV droperidol 0.625 mg before induction)
Number of subjects: 141
Study 15155323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate LA preoperatively and IV placebo before induction
Number of subjects: 141
Study 15155323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dimenhydrinate LA and droperidol
Number of subjects: 141
Study 11379334 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin, clarithromycin and rabeprazole
Number of subjects: 193
Study 11379334 — intervention group
Group type: EXPERIMENTAL
Intervention: tinidazole, clarithromycin and ranitidine bismuth citrate
Number of subjects: 193
Study 11379334 — intervention group
Group type: EXPERIMENTAL
Intervention: tinidazole, clarithromycin and rabeprazole
Number of subjects: 193
Study 11379334 — intervention group
Group type: COMPARATOR
Intervention: tinidazole, tetracycline, bismuth and rabeprazole
Number of subjects: 193
Study 9672795 — intervention group
Group type: EXPERIMENTAL
Intervention: PGTP with adjunctive subconjunctival 5-fluorouracil (5.0 +/- 1.3 injections of 5 mg each, total of 24.8 mg)
Number of subjects: 74
Study 9672795 — intervention group
Group type: COMPARATOR
Intervention: PGTP alone (control group)
Number of subjects: 74
Study 9209607 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at 50 seconds
Number of subjects: 30
Study 9209607 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at 60 seconds
Number of subjects: 30
Study 9209607 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 30
Study 1662637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days (Group I)
Number of subjects: 84
Study 1662637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg b.i.d. on day 1, followed by 250 mg once daily on days 2 to 5 (Group II)
Number of subjects: 84
Study 6126900 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 0
Study 6126900 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 0
Study 6126900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31454777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU every other week for 96 weeks
Number of subjects: 181
Study 31454777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 29543838 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation bias modification training
Number of subjects: 173
Study 29543838 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 173
Study 29543838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training conditions (Interpretation and Placebo)
Number of subjects: 173
Study 27122462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILMA)
Number of subjects: 120
Study 27122462 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (Group T)
Number of subjects: 120
Study 24886676 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based psychosexual support intervention (six sessions delivered by trained practitioners)
Number of subjects: 68
Study 24886676 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based psychosexual support intervention
Number of subjects: 68
Study 24886676 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual follow-up hospital appointments)
Number of subjects: 68
Study 24886676 — intervention group
Group type: COMPARATOR
Intervention: Economic analysis of the intervention
Number of subjects: 68
Study 21988153 — intervention group
Group type: COMPARATOR
Intervention: Providing fabricated feedback indicating above average performance in older women (71 years)
Number of subjects: 2
Study 21988153 — intervention group
Group type: COMPARATOR
Intervention: A simple statement suggesting peers usually do well on the task in older women (64 years)
Number of subjects: 2
Study 20649469 — intervention group
Group type: EXPERIMENTAL
Intervention: Red environment
Number of subjects: 36
Study 20649469 — intervention group
Group type: EXPERIMENTAL
Intervention: Green environment
Number of subjects: 36
Study 20649469 — intervention group
Group type: EXPERIMENTAL
Intervention: Darkness
Number of subjects: 36
Study 20649469 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 36
Study 18981627 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine combination
Number of subjects: 58
Study 18981627 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 58
Study 18981627 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 58
Study 15793051 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 120
Study 15793051 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 120
Study 15793051 — intervention group
Group type: COMPARATOR
Intervention: Control (standard prophylactic regimen of oral beta blocker)
Number of subjects: 120
Study 11840182 — intervention group
Group type: EXPERIMENTAL
Intervention: High unsaturated 'modified' butter feeding
Number of subjects: 20
Study 11840182 — intervention group
Group type: COMPARATOR
Intervention: Saturated 'control' butter feeding
Number of subjects: 20
Study 9847434 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 454
Study 9847434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 7781487 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbomer gel Lubrithal (Leo viscous eye gel)
Number of subjects: 40
Study 7781487 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl alcohol (Liquifilm, Allergan)
Number of subjects: 40
Study 3166361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 to 2000 mg daily)
Number of subjects: 31
Study 3166361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg daily)
Number of subjects: 31
Study 29724198 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg
Number of subjects: 42
Study 29724198 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 27290935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy (FOB)‐guided intubation
Number of subjects: 44
Study 27290935 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT) obturated with an inflated esophageal stethoscope
Number of subjects: 44
Study 24257969 — intervention group
Group type: EXPERIMENTAL
Intervention: Early once‐daily physical therapy plus a novel, progressive, twice‐daily cognitive therapy protocol
Number of subjects: 87
Study 24257969 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 87
Study 24257969 — intervention group
Group type: EXPERIMENTAL
Intervention: Early once‐daily physical therapy
Number of subjects: 87
Study 24257969 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Usual care, Early once‐daily physical therapy, Early once‐daily physical therapy plus cognitive therapy)
Number of subjects: 87
Study 22409388 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 10 μg/h
Number of subjects: 198
Study 22409388 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 20 μg/h
Number of subjects: 198
Study 22409388 — intervention group
Group type: COMPARATOR
Intervention: Vicodin (hydrocodone/acetaminophen)
Number of subjects: 198
Study 21031292 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation programme
Number of subjects: 741
Study 21031292 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 741
Study 18605968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control of hypertension (mean dose of methyldopa 1267±406 mg)
Number of subjects: 125
Study 18605968 — intervention group
Group type: COMPARATOR
Intervention: Less tight control of hypertension
Number of subjects: 125
Study 18605968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control of hypertension
Number of subjects: 125
Study 16189305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated Cambridge Cup
Number of subjects: 50
Study 16189305 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Cambridge Cup
Number of subjects: 50
Study 16189305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated components
Number of subjects: 50
Study 16189305 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall scores
Number of subjects: 50
Study 14622489 — intervention group
Group type: EXPERIMENTAL
Intervention: Public decision-making
Number of subjects: 0
Study 14622489 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related comparisons
Number of subjects: 0
Study 14622489 — intervention group
Group type: COMPARATOR
Intervention: Private decision-making
Number of subjects: 0
Study 14622489 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals
Number of subjects: 0
Study 14622489 — intervention group
Group type: EXPERIMENTAL
Intervention: Public sample
Number of subjects: 0
Study 10659898 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloving method
Number of subjects: 300
Study 10659898 — intervention group
Group type: COMPARATOR
Intervention: Single-gloving method
Number of subjects: 300
Study 10064358 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion using a PALL medical leukocyte filter during cardiopulmonary bypass
Number of subjects: 10
Study 10064358 — intervention group
Group type: COMPARATOR
Intervention: Control group with only an arterial line filter without leukodepletion
Number of subjects: 10
Study 10064358 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion using a PALL medical leukocyte filter
Number of subjects: 10
Study 1486160 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg flumazenil
Number of subjects: 30
Study 1486160 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 6428368 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol/day)
Number of subjects: 23
Study 6428368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6428368 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 23
Study 31859438 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus‐eluting stent (O‐SES)
Number of subjects: 372
Study 31859438 — intervention group
Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus-eluting stent (R‐ZES)
Number of subjects: 372
Study 29413240 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoVas BRS
Number of subjects: 560
Study 29413240 — intervention group
Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 560
Study 27277674 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 60
Study 27277674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed tracheal tube
Number of subjects: 60
Study 27277674 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed tracheal tube
Number of subjects: 60
Study 27277674 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 24609724 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP: 32% protein, 41% carbohydrate)
Number of subjects: 36
Study 24609724 — intervention group
Group type: COMPARATOR
Intervention: Higher-carbohydrate diet (HC: 20% protein, 58% carbohydrate)
Number of subjects: 36
Study 24609724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (HP and HC)
Number of subjects: 36
Study 24609724 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein intake
Number of subjects: 36
Study 21933335 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC Risk Calculator recommendation for biopsy (P(posb) ≥20%)
Number of subjects: 443
Study 21933335 — intervention group
Group type: COMPARATOR
Intervention: ERSPC Risk Calculator recommendation for no biopsy
Number of subjects: 443
Study 21933335 — intervention group
Group type: COMPARATOR
Intervention: Biopsy against the recommendation of the RC
Number of subjects: 443
Study 21933335 — intervention group
Group type: COMPARATOR
Intervention: Biopsy recommended due to elevated PSA level (≥ 3 ng/mL)
Number of subjects: 443
Study 21933335 — intervention group
Group type: COMPARATOR
Intervention: Patient's desire for certainty
Number of subjects: 443
Study 20535457 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0837 450 mg extended‐release formulation once daily for 8 days
Number of subjects: 30
Study 20535457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine co-administered on Days 6‐8 during both treatment periods
Number of subjects: 30
Study 20535457 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0837
Number of subjects: 30
Study 17650832 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled beclomethasone (1,500 microg/d)
Number of subjects: 64
Study 17650832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16271314 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion XL 150-300 mg
Number of subjects: 1042
Study 16271314 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1042
Study 12142116 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL high-dose group (mean 192 mg)
Number of subjects: 1614
Study 12142116 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL low-dose group (mean 76 mg)
Number of subjects: 1614
Study 12142116 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1614
Study 10738353 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 10738353 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA) with primary stent implantation
Number of subjects: 0
Study 7755050 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural tube defect group (27 women)
Number of subjects: 58
Study 7755050 — intervention group
Group type: COMPARATOR
Intervention: Control group (31 women)
Number of subjects: 58
Study 7755050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 1968672 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 40
Study 1968672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1968672 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (after 6 weeks chronic administration)
Number of subjects: 40
Study 6771137 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐methylene diophosphonate
Number of subjects: 0
Study 6771137 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐ethane hydroxy diphosphonate
Number of subjects: 0
Study 30685677 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D (CaD) supplementation
Number of subjects: 16801
Study 30685677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16801
Study 30685677 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 25‐hydroxyvitamin D serum levels
Number of subjects: 16801
Study 28271251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin added to metformin
Number of subjects: 5535
Study 28271251 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride added to metformin/sitagliptin
Number of subjects: 5535
Study 28271251 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide added to metformin/sitagliptin
Number of subjects: 5535
Study 28271251 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide added to metformin/sitagliptin
Number of subjects: 5535
Study 28271251 — intervention group
Group type: COMPARATOR
Intervention: Acarbose added to metformin/sitagliptin
Number of subjects: 5535